Biotech

Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

TUSTIN, CA: 60% Improvement in Median Overall Survival in Patients Treated With Bavituximab Plus Docetaxel; Data Support Advancing Bavituximab Into Phase III Development ...

Alethia Biotherapeutics Announces Issuance of a Japanese Patent for Monoclonal Antibodies Targeting Siglec-15

MONTREAL, QUEBEC: ...

AdvantageMS and Reltio Deliver Complex Affiliation Data for Life Sciences

FORT WASHINGTON, PA and PALO ALTO, CA: The Partnership Offers a Turnkey Affiliation Data Management Application on the Reltio's Big Data Platform, and Is Fully Integrated With Healthcare Provider Data From AdvantageMS ...

Agennix AG Schedules Fiscal Year 2012 Reporting Date and Conference Call on March 28

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ: ...

Alchemia Achieves $3.4 Million Quarterly Fondaparinux Profit Share

BRISBANE, AUSTRALIA: ...

Platino Energy Corp. Announces Completion of CEO Transition

CALGARY, ALBERTA: ...

NewBridge Pharmaceuticals to Commercialize the verifi(R) Prenatal Test

DUBAI, UNITED ARAB EMIRATES: New Non-Invasive Prenatal Test Now Available to Patients in the Middle East, Turkey, Africa, and Caspian Regions ...

Theratechnologies to Announce Financial Results for Fiscal Year 2012

MONTREAL, QUEBEC: ...

Crown Marketing Patents Approved and Registered in South Africa

CHAPEL HILL, NC: ...

Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer

TUSTIN, CA: Top-Line Results Demonstrate Signs of Anti-Tumor Activity in Difficult to Treat Patient Population; Company Evaluating Next Steps for Advancing Bavituximab Pancreatic Program ...